Kiniksa Pharmaceuticals, Ltd. - (KNSA) News

Kiniksa Pharmaceuticals, Ltd. - (KNSA): $16.91

0.03 (+0.18%)

POWR Rating

Component Grades

Momentum

D

Stability

D

Sentiment

Quality

C

Add KNSA to Watchlist
Sign Up

Filter KNSA News Items

KNSA News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

KNSA News Highlights

  • For KNSA, its 30 day story count is now at 2.
  • Over the past 8 days, the trend for KNSA's stories per day has been choppy and unclear. It has oscillated between 1 and 1.

Latest KNSA News From Around the Web

Below are the latest news stories about KINIKSA PHARMACEUTICALS LTD that investors may wish to consider to help them evaluate KNSA as an investment opportunity.

Chief Accounting Officer Michael Megna Sells 9,316 Shares of Kiniksa Pharmaceuticals Ltd (KNSA)

Michael Megna, Chief Accounting Officer of Kiniksa Pharmaceuticals Ltd (NASDAQ:KNSA), has sold 9,316 shares of the company on December 19, 2023, according to a recent SEC Filing.

Yahoo | December 23, 2023

The 3 Most Undervalued Biotech Stocks to Buy in December

Biotech is an increasing area of interest in the financial markets, line your portfolio up with these winning biotech stocks.

Gabriel Osorio-Mazzilli on InvestorPlace | December 15, 2023

Kiniksa Pharmaceuticals (KNSA) Up 14.7% YTD: Here's How

Kiniksa Pharmaceuticals (KNSA) enjoys a good run in the year on the back of solid revenue growth and pipeline updates.

Yahoo | November 24, 2023

Wall Street Analysts See a 70.27% Upside in Kiniksa Pharmaceuticals, Ltd. (KNSA): Can the Stock Really Move This High?

The average of price targets set by Wall Street analysts indicates a potential upside of 70.3% in Kiniksa Pharmaceuticals, Ltd. (KNSA). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Yahoo | November 20, 2023

7 Underappreciated Biotech Stocks to Pick Up on the Cheap

Amid some rising questions for the economy, value-seeking investors may want to consider underappreciated biotech stocks.

Josh Enomoto on InvestorPlace | November 10, 2023

Here's Why We're Not At All Concerned With Kiniksa Pharmaceuticals' (NASDAQ:KNSA) Cash Burn Situation

We can readily understand why investors are attracted to unprofitable companies. For example, although...

Yahoo | November 4, 2023

Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Q3 2023 Earnings Call Transcript

Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Q3 2023 Earnings Call Transcript October 31, 2023 Operator: Good day and thank you for standing by. Welcome to the Kiniksa Pharmaceuticals Third Quarter 2023 Earnings Conference Call. At this time, all participants are in a listen-only mode. After the speakers’ presentation, there will be a question-and-answer session. [Operator Instructions] Please […]

Yahoo | November 1, 2023

Q3 2023 Kiniksa Pharmaceuticals Ltd Earnings Call

Q3 2023 Kiniksa Pharmaceuticals Ltd Earnings Call

Yahoo | November 1, 2023

Kiniksa Pharmaceuticals, Ltd. (KNSA) Reports Q3 Loss, Tops Revenue Estimates

Kiniksa Pharmaceuticals, Ltd. (KNSA) delivered earnings and revenue surprises of -11.11% and 7.23%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | October 31, 2023

Kiniksa Pharmaceuticals Reports Third Quarter 2023 Financial Results and Recent Portfolio Execution

– ARCALYST® (rilonacept) Q3 2023 net product revenue of $64.8 million, representing ~94% year-over-year growth – – KPL-404 Phase 2 rheumatoid arthritis data from Cohorts 1-3 now expected in Q1 2024 – – Cash reserves of $201 million expected to fund operations into at least 2027 – – Conference call and webcast scheduled for 8:30 am ET today – HAMILTON, Bermuda, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (Kiniksa), a biopharmaceutical company with a pipeline of

Yahoo | October 31, 2023


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!